PSMA PET/CT 在中危前列腺癌分期中的作用
本文系统评价 PSMA PET/CT 在中危前列腺癌原发分期中的诊断价值。纳入 16 项研究,阳性率 2.2%–50.0%,13 项研究合并阳性率为 9%(95%CI 6–11%),淋巴结及转移灵敏度仅 33%(95%CI 14–60%)。结论认为中危患者中 PSMA PET/CT 产出率低,需前瞻性研究明确其作用。
要点
- 中危前列腺癌 PSMA PET/CT 合并阳性率 9%(95%CI 6–11%)
- ISUP GG 2 阳性率 2.2%–21.4%,GG 3 为 13.6%–33.3%
- 淋巴结及转移灵敏度低,仅 33%(95%CI 14–60%)
核心结论
- 中危前列腺癌原发分期中 PSMA PET/CT 阳性产出率低。
- 现有数据不足以指导其用于有利与不利亚组的区分。
- 需稳健前瞻性研究明确其对临床决策及预后的价值。
研究设计与样本
- 系统检索评估 PSMA PET/CT 用于初诊中危前列腺癌原发分期的研究。
- 中危定义依据 EAU/NCCN 标准或 Gleason 评分 7(ISUP GG 2–3)。
- 共纳入 16 项研究,其中 13 项纳入合并分析。
主要发现
- 16 项研究报告的中危前列腺癌阳性率范围为 2.2%–50.0%。
- 13 项研究合并分析显示 PSMA PET/CT 阳性率为 9%(95%CI 6–11%)。
- ISUP GG 2 阳性率 2.2%–21.4%,ISUP GG 3 为 13.6%–33.3%(基于两项研究)。
- 中危男性中淋巴结及转移总体灵敏度低,为 33%(95%CI 14–60%)。
关键数值与推荐
- 中危定义采用 EAU/NCCN 标准或 Gleason 评分 7(ISUP GG 2–3)。
- 主要结局为总体阳性扫描,即淋巴结或远处转移。
- 次要分析诊断准确性,包括灵敏度、特异度、阳性预测值及阴性预测值。
临床怎么用
- 中危前列腺癌患者原发分期中应审慎使用 PSMA PET/CT,避免过度检查。
- 解读阳性结果时需注意其灵敏度较低,阴性结果不能完全排除淋巴结或转移。
- 目前证据不足以支持在中危亚组中常规推荐 PSMA PET/CT。
局限性
- 纳入研究样本量小。
- 研究设计多为回顾性。
- 组织病理学确认有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To synthesise data evaluating the diagnostic utility of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in intermediate-risk prostate cancer (PCa), as its role in intermediate-risk PCa remains uncertain. METHODS: A systematic search was conducted for studies evaluating PSMA PET/CT in primary staging of newly diagnosed European Association of Urology (EAU)/National Comprehensive Cancer Network (NCCN) intermediate-risk, or Gleason Score 7 (International Society of Urological Pathology [ISUP] Grade Group [GG] 2-3) PCa. The primary outcome was overall positive scans (lymph nodes or distant metastases). We also secondarily analysed diagnostic accuracy measuring sensitivity, specificity, positive predictive value, and negative predictive value. RESULTS: In total, 16 studies reported positivity rates ranging from 2.2% to 50.0% in intermediate-risk PCa. A pooled analysis of 13 studies found a PSMA PET/CT positivity rate of 9% (95% confidence interval [CI] 6-11%). In ISUP GG 2 PCa, positivity ranged from 2.2% to 21.4%, compared to 13.6-33.3% in ISUP GG 3 PCa (across two studies). The overall nodal and metastatic sensitivity of PSMA PET/CT was low in intermediate-risk men, 33% (95% CI 14-60%). Limitations included small sample sizes, retrospective designs, and limited histopathological confirmation. CONCLUSION: For primary staging in intermediate-risk PCa PSMA PET/CT showed a low yield. Limited data exist to guide its use in favourable vs unfavourable subgroups. Robust, prospective studies are needed to define its role in clinical decision-making, further prognostic benefits, and to inform future guidelines.
引用
- Bonaddio J, Carll J, Eapen R, et al. The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer. BJU Int. 2025. PMID: 41025962. doi:10.1111/bju.70015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。